indazoles has been researched along with Breast Cancer in 149 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (2.01) | 18.7374 |
| 1990's | 26 (17.45) | 18.2507 |
| 2000's | 13 (8.72) | 29.6817 |
| 2010's | 87 (58.39) | 24.3611 |
| 2020's | 20 (13.42) | 2.80 |
| Authors | Studies |
|---|---|
| Furugen, A; Iseki, K; Kobayashi, M; Nadai, T; Narumi, K; Saito, Y | 1 |
| Casey, PJ; Tang, J; Wang, M | 1 |
| Bellesoeur, A; Beuzeboc, P; Diéras, V; Neuzillet, C; Rodrigues, M; Saint-Ghislain, M; Salaün, H; Stern, MH | 1 |
| Ala-Hongisto, H; Bertula, K; Elo, LL; Euro, L; Heikkilä, P; Hollmann, B; Hukkinen, K; Ikkala, O; Joensuu, H; Junttila, MR; Kivento, M; Klefström, J; Kovanen, P; Leidenius, M; Martikainen, L; Mattson, J; Meretoja, T; Metcalfe, C; Monni, O; Munne, PM; Mutka, M; Nevalaita, L; Patrikainen, L; Peura, A; Pokki, J; Pouwels, J; Räty, I; Ruuska, J; Sahu, B; Salmela, M; Suomi, T; Väänänen, J; Yavuz, K | 1 |
| Cao, Y; Guo, B; Kong, D; Lu, Z; Meng, X; Yang, Y; Zhang, D | 1 |
| Chen, H; Cheng, M; Gao, P; Li, G; Li, H; Qin, L; Wang, L; Zhang, X | 1 |
| Aithal, KB; Albacker, LA; Banka, D; Bolduc, DM; Furman, C; Hao, MH; Irwin, S; Kim, A; Korpal, M; Larsen, N; Montesion, M; Moriarty, AD; Murugesan, K; Nguyen, TV; Prajapati, S; Puyang, X; Rimkunas, V; Sahmoud, T; Vaillancourt, FH; Wick, MJ; Wu, ZJ; Yao, S; Zeng, H; Zhang, X; Zhang, Z; Zheng, GZ; Zhu, P | 1 |
| Guan, Z; Li, J; Tang, R; Wang, X; Yang, L; Zhang, J | 1 |
| Chandarana, SP; Ernst, MS; Hao, D; Hyrcza, MD; Lysack, JT | 1 |
| Ellisen, LW; Graham, JR; Hamilton, E; Han, H; Hazard, S; Irie, H; Isakoff, SJ; Liu, MC; Pan, P; Reeves, J; Santa-Maria, CA; Shan, M; Spring, LM; Tang, Y | 1 |
| Han, X; Lu, C; Lv, S; Qiao, P; Ren, C; Sun, Y; Wang, D; Wang, L; Yang, T; Yu, Z | 1 |
| Cohen-Erez, I; Gheber, LA; Issacson, C; Laster, B; Lavi, Y; Milam, J; Rapaport, H; Shaco-Levy, R | 1 |
| Li, J; Liang, X; Shen, Q; Sun, L; Yang, J; Zhang, J; Zuo, T | 1 |
| Gai, Y; Han, N; Jiang, Y; Lan, X; Li, M; Liu, Q; Wang, Y; Yuan, L; Zhang, Y | 1 |
| Agostinetto, E; D'Amico, T; De Sanctis, R; Lorenzi, E; Santoro, A; Simonelli, M | 1 |
| Chen, HY; Fu, LS; Li, MM; Liu, M; Liu, X; Liu, Z; Ma, YY; Sun, HT; Tian, XY; Wang, Y; Wang, YF; Zhang, PC | 1 |
| Alagumuthu, M; Arumugam, NA; Arumugam, S; Shah, M; Sonaimuthu, M; Srivastava, V | 1 |
| Baltes, F; Bendas, G; Caspers, J; Henze, S; Schlesinger, M | 1 |
| Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J | 1 |
| Gabrail, N; Smith, C | 1 |
| Bakar-Ates, F; Ozkan, E | 1 |
| Ando, Y; Matsushita, H; Nishida-Fukuda, H; Tanaka, H; Tokuhiro, K; Wada, M | 1 |
| Jung, US; Kim, DH; Kim, HS; Kim, MG; Min, KW | 1 |
| Adam, V; Audeh, W; Balmaña, J; Cameron, DA; Colleoni, M; Ellard, SL; Erban, J; Goldstein, LJ; Goulioti, T; Honkoop, AH; Ignatiadis, M; Jen, KY; Johannsson, OT; Juan-Fita, MJ; Kaufman, B; Láng, I; Litière, S; Macpherson, IRJ; Mailliez, A; Manso, L; Musolino, A; Poncet, C; Razis, E; Trédan, O; Tryfonidis, K; Turner, NC; Tutt, AN; Vuylsteke, P; Zoppoli, G | 1 |
| Chen, S; Lensing, MM; Lyu, C; Wagner, KU; Weigel, RJ; Ye, Y | 1 |
| Austreid, E; Eikesdal, HP; Knappskog, S; Lønning, PE; Svanberg, IR; Yndestad, S | 1 |
| Morimoto-Kamata, R; Yui, S | 1 |
| Beijnen, JH; Gebretensae, A; Hughes, L; Kansra, V; Rosing, H; Sanghvi, M; Schellens, JHM; Tibben, MM; van Andel, L; Zhang, Z | 1 |
| Chen, J; Feng, Z; Gao, J; Gatza, ML; Haffty, BG; Hu, W; Huang, S; Khella, CA; Liu, J; Tomsky, K; White, E; Wu, H; Xia, D; Xie, H; Yue, X; Zhang, C; Zhao, Y | 1 |
| Chen, SJ; Chen, YK; Cheng, FT; Chou, YY; Lapke, N; Ou-Yang, F; Tung, KC | 1 |
| Cheeti, S; Hou, HH; Jia, W; Li, J; Liu, L; Nagapudi, K; Nauka, E | 1 |
| Qi, Y; Qiao, Q; Qin, X; Song, Q; Wu, T; Yang, C; Zhang, Z | 1 |
| Jiang, W; Liu, S; Tang, Y; Yan, M | 1 |
| Li, J; Liang, X; Shen, Q; Wang, Y; Yang, X; Yin, Y; Zhang, J; Zuo, T | 1 |
| Gillard, M; Lee, JM; Lipkowitz, S; Zimmer, AS | 1 |
| Basaga, H; Gul, O; Karakas, B; Kutuk, O; Ozmay, Y | 1 |
| Domchek, SM | 1 |
| Bian, X; Cheng, H; Gao, J; Li, T; Liu, P; Luo, F; Rui, C; Usman, MW; Zheng, T | 1 |
| Berindan-Neagoe, I; Calin, GA; Chen, L; Dan Dumitru, C; Fu, X; Fuentes-Mattei, E; Huang, B; Irimie, A; Ivan, C; Jung, EJ; Lehrer, M; Ling, H; Mafra, ACP; Monroig-Bosque, MDM; Monroig-Bosque, PDC; Nagvekar, R; Nikonowicz, EP; Nouraee, N; Pileczki, V; Redis, RS; Rivera, C; Shah, MY; Zhang, S; Zhang, X | 1 |
| Cresta, S; Damian, S; Gendreau, S; Mayer, IA; Morrissey, KM; Ng, VW; Rooney, I; Schöffski, P; Singel, SM; Spoerke, JM; Wildiers, H; Winer, E | 1 |
| Al-Kawaz, A; Ali, R; Band, V; Green, AR; Madhusudan, S; Mesquita, KA; Miligy, IM; Mirza, S; Rakha, EA; Seedhouse, C; Toss, MS | 1 |
| Cheeti, S; Chen, B; Gates, M; Girish, S; Hou, HH; Liu, L; Morley, R; Musib, L; Nelson, E; Sahasranaman, S; Walker, H | 1 |
| Baldini, C; Banerjee, S; Battisti, NML; Dumas, L; Kadambi, S; Lichtman, SM; Liposits, G; Loh, KP; Soto-Perez-de-Celis, E | 1 |
| Feng, Z; Gao, T; Lei, Q; Li, Z; Liu, Z; Peng, C; Song, X; Wang, N; Wei, W; Xia, Y; Xiong, L; Ye, T; Yu, L | 1 |
| Bailey, A; Buttar, D; Carbajo, RJ; Curwen, J; Davey, PRJ; Davies, RDM; Degorce, SL; Donald, C; Gangl, E; Greenwood, R; Groombridge, SD; Johnson, T; Lamont, S; Lawson, M; Lister, A; Morrow, CJ; Moss, TA; Pink, JH; Polanski, R; Scott, JS | 1 |
| Federico, L; Feng, B; Feng, N; Hanke, J; Ma, X; Marszalek, JR; Mikule, K; Mills, GB; Ramaswamy, S; Sun, K; Vellano, CP; Wang, J; Wang, Z; Xiao, Y | 1 |
| Cheng, Y; Hou, Y; Pu, X; Wan, W; Wang, K; Ye, X | 1 |
| Furman, C; Hao, MH; Korpal, M; Prajapati, S; Reynolds, D; Rimkunas, V; Zheng, GZ; Zhu, P | 1 |
| Chumakova, A; Esakov, EL; Gullapalli, K; Hale, J; Jensen, J; Lathia, J; Reizes, O; Richards, EG; Torre-Healy, L; Trivedi, D; Wessely, O | 1 |
| Balmaña, J; Castroviejo-Bermejo, M; Cruz, C; de Bono, JS; Kaye, SB; Lord, CJ; Mateo, J; Oaknin, A; Serra, V; Tutt, A | 1 |
| Chan, IT; Cheeti, S; Chen, B; Cheung, KWK; Liu, L; Morley, R; Sahasranaman, S; Yoshida, K | 1 |
| Blake, RA; Chalouni, C; Chen, IP; Daemen, A; De Bruyn, T; Friedman, LS; Giltnane, JM; Guan, J; Hafner, M; Hager, JH; Hartman, SJ; Heidersbach, A; Houtman, R; Ingalla, E; Kategaya, L; Kleinheinz, T; Li, J; Martin, SE; Metcalfe, C; Modrusan, Z; Nannini, M; Oeh, J; Sampath, D; Ubhayakar, S; Wang, X; Wertz, IE; Young, A; Yu, M; Zhou, W | 1 |
| Andreu, Z; Anwar, T; Fernández, P; Gril, B; Liewehr, DJ; Masana, D; Palmieri, D; Qian, Y; Steeg, PS; Steinberg, SM; Vidal-Vanaclocha, F | 1 |
| Chen, H; Duan, C; Duan, H; Guo, N; Hu, Y; Liu, D; Shi, M; Yang, Z | 1 |
| Chou, LC; Chung, CH; Huang, CH; Huang, LJ; Kuo, SC; Lee, FY; Lee, JC; Lien, JC; Way, TD; Wu, JC | 1 |
| Gallo, KA; Wu, X | 1 |
| Baltazar, F; Miranda-Gonçalves, V; Morais-Santos, F; Paredes, J; Pinheiro, C; Pinheiro, S; Schmitt, FC; Vieira, AF | 1 |
| Ji, S; Liu, S; Shao, G; Zheng, Y; Zhou, Y | 1 |
| Wang, H; Yao, J; Zheng, J; Zou, X | 1 |
| Chang, LC; Chou, RH; Hsieh, MT; Huang, LJ; Hung, HY; Kuo, SC; Lee, FY; Lin, HY; Teng, CM; Tsai, MT; Yu, YL | 1 |
| Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W | 1 |
| Bridges, KA; Buchholz, TA; Buser, CA; Liu, H; Meyn, RE; Toniatti, C | 1 |
| Awrey, DE; Bray, MR; Cescon, DW; Che, Y; Fletcher, GC; Kiarash, R; Lin, DC; Mak, TW; Mason, JM; Pan, G; Wei, X; Yao, Y | 1 |
| Cleveland, DW; Holland, AJ | 1 |
| Glickson, JD; Heitjan, DF; Leeper, DB; Nath, K; Nelson, DS; Zhou, R | 1 |
| Bhatt, K; Bury, MJ; Fehrenbacher, L; Flynn, PJ; Geyer, CE; Goel, R; Jacobs, SA; Johannes, H; Julian, TB; Mamounas, EP; Provencher, L; Rastogi, P; Robidoux, A; Stella, PJ; Swain, SM; Tan, AR; Thirlwell, MP; Wolmark, N | 1 |
| Akare, UR; Bandaru, S; Dunna, NR; Gutlapalli, VR; Nayarisseri, A; Rajadhyax, S; Yadav, M | 1 |
| Chen, M; Cheng, H; Gao, X; Gu, C; Jiang, N; Li, X; Liu, P; Luo, F; Shi, L | 1 |
| Chu, X; Shao, F; Wang, L | 1 |
| Aparicio, AM; Bonnefous, C; Darimont, BD; Douglas, KL; Govek, SP; Grillot, KL; Hager, JH; Joseph, JD; Kahraman, M; Kaufman, JA; Lai, AG; Lee, KJ; Lu, N; Moon, MJ; Nagasawa, JY; Prudente, RY; Rix, PJ; Sensintaffar, J; Smith, ND | 1 |
| Arismendi-Macuer, M; Fuentealba, M; Guzmán, L; Knox, M; Molinari, A; Oliva, A; San Feliciano, A; Vinet, R | 1 |
| Bates, D; Bean, JR; Demidenko, E; Dillon, LM; Eastman, AR; Hosford, SR; Lewis, LD; Liu, SC; Marotti, JD; Miller, TW; Nannini, MA; Pang, J; Salphati, L; Shee, K; Yang, W; Zhang, X | 1 |
| Bundred, N; Butler, H; Derynck, M; Earl, G; Gazinska, P; Gendreau, S; Hadad, S; Hu, J; Korbie, D; Lackner, MR; Lim, L; Macaskill, J; Mainwaring, P; Parker, P; Pinder, SE; Price, R; Purushotham, A; Sarker, SJ; Schmid, P; Shia, A; Thompson, A; Trau, M; Wheatley, D; Wilson, TR; Woodman, N; Zammit, C | 1 |
| Lee, NR; Lee, SY | 1 |
| Aimi, J; Amler, LC; Chan, IT; Chen, M; Derynck, MK; Gendreau, S; Hampton, GM; Johnston, S; Krop, I; Lackner, MR; Qiu, J; Savage, H; Schmid, P; Spoerke, JM; Walter, K; Wilson, TR | 1 |
| Aparicio, A; Arrazate, A; Arteaga, CL; Bischoff, E; Blake, RA; Bonnefous, C; Brigham, D; Darimont, B; Douglas, KL; Friedman, L; Giltnane, JM; Govek, SP; Grillot, K; Guan, Z; Hager, JH; Haley, B; Heyman, RA; Ingalla, E; Joseph, JD; Julien, JD; Kahraman, M; Kategaya, L; Kaufman, J; Lackner, MR; Lai, AG; Lee, KJ; Lu, N; Manning, HC; Metcalfe, C; Moon, M; Nagasawa, JY; Nannini, MA; Nonomiya, J; Prudente, R; Qian, J; Rix, PJ; Sampath, D; Schwarz, L; Sensintaffar, J; Shao, G; Smith, ND; Tantawy, MN; Walter, K; Wertz, IE; Young, A; Zhou, W | 1 |
| Abell, F; Apt, D; Chan, S; Fehrenbacher, L; Gendreau, S; Huizing, M; Laing, R; Petrakova, K; Rooney, I; Roylance, R; Singel, S; Vuylsteke, P; Zhou, J | 1 |
| Ratain, MJ; Sweis, RF | 1 |
| Arteaga, CL; Bauer, JA; Bhola, NE; Dugger, TC; Ericsson, PG; Estrada, MV; Formisano, L; Hutchinson, KE; Jansen, VM; Knudsen, ES; Lee, KM; Moore, PD; Pishvaian, MJ; Pohlmann, PR; Riddle, DA; Sánchez, V; Sanders, ME; Wei, W; Witkiewicz, AK | 1 |
| Akita, RW; Fields, C; Friedman, LS; Junttila, TT; Lewis Phillips, GD; Parsons, K; Sampath, D; Sliwkowski, MX | 1 |
| Belvin, M; Eastham-Anderson, J; Friedman, LS; Gunter, B; Haverty, PM; Hoeflich, KP; Lee-Hoeflich, ST; Lewin-Koh, N; Murray, LJ; Sliwkowski, MX; Truong, T; Yao, E; Zhou, W | 1 |
| Kelly, RJ; Rixe, O | 1 |
| Hudder, A; Novak, RF; Zheng, J; Zukowski, K | 1 |
| Amler, LC; Belvin, M; Berry, L; Friedman, LS; Guan, J; GuhaThakurta, D; Lackner, MR; O'Brien, C; Prior, WW; Punnoose, EA; Sampath, D; Savage, H; Wallin, JJ | 1 |
| Belvin, M; Bradford, D; Edgar, KA; Prior, WW; Salphati, L; Sampath, D; Wallin, JJ; Wong, H | 1 |
| Engelman, JA; Turke, AB | 1 |
| Agulnik, M; Chia, S; Clemons, M; Dent, S; Grenci, P; Ivy, P; Leighl, NB; Oza, AM; Pritchard, KI; Taylor, SK; Wang, L | 1 |
| Belvin, M; Edgar, KA; Friedman, LS; Guan, J; Kassees, R; Prior, WW; Sampath, D; Wallin, JJ | 1 |
| Amiji, M; Duan, Z; Milane, L | 1 |
| Gril, B; Ileva, L; Liewehr, DJ; Palmieri, D; Qian, Y; Smart, D; Steeg, PS; Steinberg, SM | 1 |
| Amiji, M; Duan, ZF; Milane, L | 1 |
| Beijnen, JH; Iusuf, D; Poller, B; Schinkel, AH; Sparidans, RW; Wagenaar, E | 1 |
| Bair, AH; Bycott, P; Chan, S; Joy, AA; Kim, S; Liau, KF; Lluch, A; Rosbrook, B; Rugo, HS; Soulieres, D; Stopeck, AT; Verma, S | 1 |
| Schneider, BP; Sledge, GW | 1 |
| Ding, WJ; He, QJ; Lin, NM; Wu, HH; Yang, B; Yang, W; Zhang, C; Zheng, L; Zhu, H | 1 |
| Bronson, RT; Cheng, KA; Curtin, NJ; D'Andrea, AD; Johnson, N; Li, D; Li, YC; Moreau, LA; Newell, DR; Rodig, SJ; Shapiro, GI; Thomas, HD; Unitt, C; Walton, ZE; Wong, KK | 1 |
| Anwar, T; Bernardo, M; Choyke, P; Gril, B; Ileva, L; Liewehr, DJ; Palmieri, D; Qian, Y; Steeg, PS; Steinberg, SM | 1 |
| Ang, KK; Buchholz, T; Buser-Doepner, C; Mason, KA; Mathur, A; Milas, L; Toniatti, C; Valdecanas, D; Wang, L | 1 |
| Amiri-Kordestani, L; Swain, SM; Tan, AR | 1 |
| Biondi, G; De Martino, D; Di Dato, V; Garrone, B; Guglielmotti, A; Liguori, L; Mangano, G; Marino, N; Navas, L; Spano, D; Vastolo, V; Zollo, M | 1 |
| Cheng, HC; Cheng, Y; Li, W; Liu, Y; Ma, J; Qiu, L | 1 |
| Belmont, LD; Belvin, M; Berry, L; Friedman, LS; Guan, J; Koeppen, H; Lee, LB; Prior, WW; Sampath, D; Wallin, JJ | 1 |
| Fokialakis, N; Haroutounian, SA; Kasiotis, KM; Liekens, S; Tzanetou, E | 1 |
| Yao, J; Zheng, J; Zou, X | 1 |
| Brennan, KR; Clarke, RB; Gregson, HJ; Harrison, H; Landberg, G; Rogerson, L | 1 |
| Durante, M; Gómez, H; Goodman, V; Johnston, SR; Pandite, L; Richie, M; Slamon, D; Stemmer, SM | 1 |
| Alquati, P; Berruti, A; Bitossi, R; Bonazzi, G; Bottini, A; Bruzzi, P; Bumma, C; Castiglione, F; Danese, S; De Lena, M; De Matteis, A; DeFabiani, E; Dogliotti, L; Farris, A; Giardina, G; Gorzegno, G; Lorusso, V; Moro, G; Nuzzo, F; Sarobba, MG | 1 |
| Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Ferretti, G; Papaldo, P | 1 |
| Antimi, M; Barone, C; Botti, C; Cammilluzzi, E; Carlini, P; Conti, F; Cortesi, E; Di Cosimo, S; Di Lauro, L; Fabi, A; Ferretti, G; Giannarelli, D; Lepidini, G; Lopez, M; Marolla, P; Nistico, C; Papaldo, P; Terzoli, E; Vici, P; Vitucci, C | 1 |
| Brasch, RC; Fu, YJ; Henry, RG; Hu-Lowe, DD; Hylton, NM; Li, KL; McShane, TM; Pallavicini, MG; Park, JW; Shalinsky, DR; Wilmes, LJ | 1 |
| Antimi, M; Botti, C; Carlini, P; Ceribelli, A; Cognetti, F; Cortesi, E; Di Cosimo, S; Di Filippo, F; Di Lauro, L; Ferretti, G; Giannarelli, D; Lopez, M; Marolla, P; Mottolese, M; Naso, G; Nisticò, C; Papaldo, P; Ruggeri, EM; Terzoli, E; Vici, P | 1 |
| Brasch, RC; Fleming, LM; Gibbs, J; Henry, RG; Hu-Lowe, D; Hylton, NM; Li, KL; Lu, Y; McShane, TM; Pallavicini, MG; Park, JW; Partridge, SC; Shalinsky, DR; Wang, D; Wilmes, LJ | 1 |
| Hiraga, T; Hiraoka, M; Hirota, K; Kizaka-Kondoh, S; Yoneda, T | 1 |
| Kibble, A | 1 |
| Anderes, K; Blasina, A; Chen, E; Chen, P; Deng, Y; Grant, S; Hu, Q; Johnson, MD; Kania, RS; Kornmann, J; Lundgren, K; Ninkovic, S; Peng, Z; Register, J; Rogers, C; Teng, M; Zhu, J | 1 |
| Acton, DG; Ballard, P; Barlaam, B; Bradbury, RH; Cross, D; Ducray, R; Germain, H; Hudson, K; Klinowska, T; Magnien, F; Ogilvie, DJ; Olivier, A; Ross, HS; Smith, R; Trigwell, CB; Vautier, M; Wright, L | 1 |
| Carpano, S; Conti, F; Di Lauro, L; Giannarelli, D; Gionfra, T; Lopez, M; Paoletti, G; Pignatti, F; Vici, P | 1 |
| Bucci, L; Caponigro, F; Di Martino, N; Facchini, G; Fei, L; Iaffaioli, RV; Mantovani, G; Santangelo, M; Tortoriello, A | 1 |
| Arancia, G; Calcabrini, A; Citro, G; Meschini, S; Molinari, A | 1 |
| Ara, G; Eder, JP; Herman, TS; Holden, SA; Korbut, T; Schwartz, GN; Teicher, BA | 1 |
| Barone, C; Camoriano, A; Gardin, G; Ianniello, G; Merlini, L; Nascimben, O; Naso, C; Pronzato, P; Rosso, M; Rosso, R | 1 |
| Alquati, P; Baù, MG; Berruti, A; Bottini, A; Buniva, T; Deltetto, F; Dogliotti, L; Farris, A; Gosso, P; Monzeglio, C; Moro, G; Perroni, D; Sarobba, MG; Sussio, M; Zola, P | 1 |
| Barone, C; Contu, A; Gardin, G; Ianniello, G; Nascimben, O; Pronzato, P; Rosso, R; Sturba, F | 1 |
| Biroccio, A; D'Angelo, C; Del Bufalo, D; Laudonio, N; Sacchi, A; Soddu, S; Zupi, G | 1 |
| Bruno, T; Citro, G; Fanciulli, M; Floridi, A; Valentini, A; Zupi, G | 1 |
| Ben-Horin, H; Kaplan, O; Navon, G; Tassini, M; Vivi, A | 1 |
| Amadori, D; Gasperi-Campani, A; Roncuzzi, L; Zoli, W | 1 |
| Bearzatto, A; De Marco, C; Gornati, D; Silvestrini, R; Zaffaroni, N | 1 |
| Borsellino, N; Colucci, G; Gebbia, N; Gebbia, V; Giotta, F; Latteri, MA; Milia, V; Testa, A; Valdesi, M | 1 |
| Baù, MG; Berruti, A; Bottini, A; Buniva, T; Danese, S; Dogliotti, L; Farris, A; Moro, G; Porcile, G; Richiardi, G; Zola, P | 1 |
| Amadori, D; Cariello, S; De Matteis, A; Ferrari, M; Frassineti, GL; Lombardi, A; Mustacchi, G; Nanni, O; Nascimben, O; Santoro, A; Scarpi, E; Zoli, W | 1 |
| D'Ottavio, AM; Fabi, A; Garufi, C; Milella, M; Nisticò, C; Terzoli, E; Vaccaro, A | 1 |
| Ash, E; Cohen, JS; Kaplan, O; Mardor, Y; Ringel, I; Roth, Y; Ruiz-Cabello, J; Sterin, M | 1 |
| Amadori, A; Amadori, D; Flamigni, A; Frassineti, GL; Magni, E; Nanni, O; Savini, S; Volpi, A; Zoli, W | 1 |
| Citro, G; Cucco, C; Verdina, A; Zupi, G | 1 |
| Button, D; de Graeff, A; Glaholm, J; Leach, MO; Mansi, JL; Newell, DR; Payne, G; Smith, IE | 1 |
| Epelbaum, R; Frei, E; Herman, TS; Holden, SA; Liu, SD; Teicher, BA | 1 |
| Button, D; Catanese, B; Hardy, J; Jenns, K; Mansi, J; Newell, DR; Picollo, R; Smith, IE | 1 |
| Classen, S; Flath, B; Kovacs, S; Possinger, K; Wagner, H; Wilmanns, W | 1 |
| Amoroso, D; Gardin, G; Guido, T; Miglietta, L; Pace, M; Pronzato, P; Repetto, L; Rosso, R | 1 |
| Ballatore, P; Calabresi, F; Calabró, A; Curcio, CG; Di Lauro, L; Di Palma, M; Foggi, CM; Giannarelli, D; Marolla, P; Paoletti, G | 1 |
| Benson, AB; Neuberg, DS; Pandya, KJ; Robins, HI; Tormey, DC | 1 |
| Arcangeli, G; Marini, G; Marpicati, P; Meriggi, F; Montini, E; Simoncini, E; Zaniboni, A | 1 |
| Brann, TW; Frei, E; Holden, SA; Rosbe, KW; Teicher, BA | 1 |
| Amoroso, D; Bertelli, G; Ciottoli, GB; Conte, PF; Cusimano, MP; Gulisano, M; Lionetto, R; Pronzato, P; Rosso, R | 1 |
| Band, PR; Coppin, CM; Eisenhauer, EA; Maroun, J; Pritchard, K; Stewart, D; Wilson, K | 1 |
10 review(s) available for indazoles and Breast Cancer
| Article | Year |
|---|---|
[Homologous recombination deficiency and PARP inhibitors in therapeutics].
Topics: Breast Neoplasms; DNA Damage; DNA Repair-Deficiency Disorders; Drug Resistance, Neoplasm; Female; Genes, BRCA1; Genes, BRCA2; Homologous Recombination; Humans; Indazoles; Indoles; Male; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Recombinational DNA Repair | 2022 |
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Update on PARP Inhibitors in Breast Cancer.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Humans; Indazoles; Indoles; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival | 2018 |
PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Topics: Aged; Aged, 80 and over; Breast Neoplasms; DNA Repair; Female; Genes, BRCA1; Genes, BRCA2; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Synthetic Lethal Mutations | 2019 |
Estrogen Receptor Covalent Antagonists: The Best Is Yet to Come.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Estrogen Receptor Antagonists; Female; Humans; Indazoles; Receptors, Estrogen | 2019 |
A decade of clinical development of PARP inhibitors in perspective.
Topics: BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Genomic Instability; Humans; Indazoles; Indoles; Ovarian Neoplasms; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors | 2019 |
Axitinib (AG-013736).
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Biological Availability; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Imidazoles; Indazoles; Neoplasms; Pancreatic Neoplasms; Thyroid Neoplasms | 2010 |
Pazopanib for the treatment of breast cancer.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Indazoles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sulfonamides | 2012 |
Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Humans; Indazoles; Lung Neoplasms; Male; Ovarian Neoplasms; Safety | 2003 |
Lonidamine in metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Indazoles | 1991 |
29 trial(s) available for indazoles and Breast Cancer
| Article | Year |
|---|---|
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses | 2021 |
Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Breast Neoplasms; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Fallopian Tube Neoplasms; Female; Humans; Indazoles; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Radioactive Tracers; Tandem Mass Spectrometry | 2018 |
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cohort Studies; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Letrozole; Middle Aged; Nausea; Paclitaxel; Sulfonamides; Trastuzumab | 2018 |
Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cinnamates; Cross-Over Studies; Drug Compounding; Excipients; Female; Food-Drug Interactions; Humans; Indazoles; Meglumine; Middle Aged; Receptors, Estrogen; Sodium Dodecyl Sulfate; Surface-Active Agents | 2018 |
GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers; Breast Neoplasms; Cinnamates; Coproporphyrins; Dose-Response Relationship, Drug; Drug Interactions; Feasibility Studies; Female; Half-Life; Humans; Indazoles; Liver-Specific Organic Anion Transporter 1; Middle Aged; Receptors, Estrogen; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2019 |
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Indazoles; Lymph Nodes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Sulfonamides | 2015 |
Pictilisib stalls advanced ER+/PR+ breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Estradiol; Female; Fulvestrant; Humans; Indazoles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Receptors, Estrogen; Receptors, Progesterone; Sulfonamides | 2015 |
Phase II Randomized Preoperative Window-of-Opportunity Study of the PI3K Inhibitor Pictilisib Plus Anastrozole Compared With Anastrozole Alone in Patients With Estrogen Receptor-Positive Breast Cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Drug Synergism; Female; Humans; Indazoles; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Phosphoinositide-3 Kinase Inhibitors; Postmenopause; Preoperative Care; Protein Kinase Inhibitors; Receptor, ErbB-2; Receptors, Estrogen; Sulfonamides; Triazoles | 2016 |
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Estrogens; Female; Fulvestrant; Humans; Indazoles; Middle Aged; Mutation; Protein Kinase Inhibitors; Sulfonamides | 2016 |
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-c
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Receptor, ErbB-2; Sulfonamides | 2016 |
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Breast Neoplasms; Disease Progression; ErbB Receptors; Female; Humans; Indazoles; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Platelet-Derived Growth Factor; Pyrimidines; Sulfonamides | 2010 |
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypertension; Imidazoles; Indazoles; Middle Aged; Mucositis; Neoplasm Proteins; Neutropenia; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Taxoids; Thrombophilia | 2011 |
A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Humans; Indazoles; Lapatinib; Middle Aged; Neoplasm Staging; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sulfonamides; Treatment Outcome | 2013 |
Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Indazoles; Logistic Models; Middle Aged; Survival Analysis | 2002 |
Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Filgrastim; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Indazoles; Middle Aged; Recombinant Proteins; Survival Rate | 2003 |
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Erythropoiesis; Female; Granulocyte Colony-Stimulating Factor; Humans; Indazoles | 2006 |
Intrapatient comparison of single-agent epirubicin with or without lonidamine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Survival Rate | 1995 |
Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Epirubicin; Female; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indazoles; Interferon alpha-2; Interferon-alpha; Menopause; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Postmenopause; Premenopause; Recombinant Proteins | 1995 |
The role of lonidamine in the treatment of breast cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Indazoles; Middle Aged; Survival Analysis | 1993 |
Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Synergism; Epirubicin; Female; Humans; Indazoles; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Analysis; Treatment Outcome | 1996 |
Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Indazoles; Middle Aged | 1996 |
Cisplatin and epirubicin plus oral lonidamine as first-line treatment for metastatic breast cancer: a phase II study of the Southern Italy Oncology Group (GOIM).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis | 1997 |
Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Epirubicin; Female; Humans; Indazoles; Infusions, Intravenous; Middle Aged; Nausea; Pilot Projects; Thrombocytopenia; Treatment Outcome; Vomiting | 1998 |
Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Protocols; Doxorubicin; Drug Interactions; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis | 1998 |
Weekly epirubicin plus lonidamine in advanced breast carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Synergism; Epirubicin; Female; Humans; Indazoles; Injections, Intravenous; Liver Neoplasms; Middle Aged | 1999 |
Lonidamine in high-risk breast cancer patients.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Indazoles; Middle Aged; Remission Induction; Vindesine | 1991 |
Fluorouracil, doxorubicin, and cyclophosphamide versus fluorouracil, doxorubicin, and cyclophosphamide plus lonidamine for the treatment of advanced breast cancer: a multicentric randomized clinical study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Indazoles; Middle Aged; Prospective Studies; Remission Induction; Time Factors | 1991 |
Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Evaluation; Drugs, Investigational; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis | 1990 |
Mitomycin-C, vinblastine, and lonidamine as salvage treatment of advanced breast cancer. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Indazoles; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Pilot Projects; Vinblastine | 1990 |
111 other study(ies) available for indazoles and Breast Cancer
| Article | Year |
|---|---|
Pharmacological Inhibition of MCT4 Reduces 4-Hydroxytamoxifen Sensitivity by Increasing HIF-1α Protein Expression in ER-Positive MCF-7 Breast Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; MCF-7 Cells; Monocarboxylic Acid Transporters; Muscle Proteins; Propionates; Receptors, Estrogen; Tamoxifen | 2021 |
Suppression of isoprenylcysteine carboxylmethyltransferase compromises DNA damage repair.
Topics: Animals; Apoptosis; Benzamides; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Repair; Female; Genetic Vectors; HEK293 Cells; Humans; Indazoles; MAP Kinase Signaling System; Mice; Mice, SCID; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Protein Methyltransferases; Ribonucleosides; RNA, Small Interfering; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Compressive stress-mediated p38 activation required for ERα + phenotype in breast cancer.
Topics: Breast Neoplasms; Case-Control Studies; Cell Line, Tumor; Cinnamates; Collagen; Drug Combinations; Enhancer of Zeste Homolog 2 Protein; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histones; Humans; Indazoles; Laminin; Mammary Glands, Human; Mechanotransduction, Cellular; p38 Mitogen-Activated Protein Kinases; Phenotype; Proteoglycans; Tamoxifen; Tissue Culture Techniques; Transcriptome | 2021 |
Discovery of Thieno[2,3-
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogen Receptor alpha; Female; Humans; Indazoles; MCF-7 Cells; Mice; Receptors, Estrogen; Thiophenes | 2022 |
GDC-0941 activates integrin linked kinase (ILK) expression to cause resistance to GDC-0941 in breast cancer by the tumor necrosis factor (TNF)-α signaling pathway.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Indazoles; Integrins; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sulfonamides; Tumor Necrosis Factor-alpha | 2022 |
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.
Topics: Breast Neoplasms; Clinical Trials as Topic; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Indazoles; Neoplasm Recurrence, Local; Pyridines | 2022 |
Carrier-free prodrug nanoparticles based on lonidamine and cisplatin for synergistic treatment of breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cisplatin; Female; Glutathione; Humans; Indazoles; Nanoparticles; Prodrugs | 2022 |
TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report.
Topics: Benzamides; Breast Neoplasms; Carcinoma; Gene Fusion; Humans; Indazoles | 2022 |
Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer.
Topics: Breast Neoplasms; Female; Humans; Indazoles; Neoadjuvant Therapy; Pilot Projects; Piperidines | 2022 |
Phosphorylation of HSF1 by PIM2 Induces PD-L1 Expression and Promotes Tumor Growth in Breast Cancer.
Topics: Aminopyridines; Animals; Autophagy; B7-H1 Antigen; Benzylidene Compounds; Breast Neoplasms; Carboplatin; F-Box-WD Repeat-Containing Protein 7; Female; Gene Expression Regulation, Neoplastic; Heat Shock Transcription Factors; Humans; Indazoles; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasm Proteins; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Stability; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering; Substrate Specificity; Thiazolidinediones; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2019 |
Antitumor Effect of Lonidamine-Polypeptide-Peptide Nanoparticles in Breast Cancer Models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Female; Humans; Indazoles; Mice, Inbred BALB C; Mitochondria; Nanoparticles; Peptides; Xenograft Model Antitumor Assays | 2019 |
Coadministration of chemotherapy and PI3K/Akt pathway treatment with multistage acidity/CathB enzyme-responsive nanocarriers for inhibiting the metastasis of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Carriers; Female; Humans; Indazoles; Maleic Anhydrides; Mice; Nanoparticles; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Polyethyleneimine; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2019 |
Topics: Animals; Breast Neoplasms; Carbon Radioisotopes; Cell Line, Tumor; Drug Evaluation, Preclinical; Female; Hepatobiliary Elimination; Heterografts; Humans; Indazoles; Inhibitory Concentration 50; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Positron-Emission Tomography; Radiopharmaceuticals; Signal Transduction; Sulfonamides; Tissue Distribution | 2019 |
Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report.
Topics: Adolescent; Breast Neoplasms; Combined Modality Therapy; Endosonography; Female; Hemangiosarcoma; Humans; Indazoles; Mastectomy; Primary Ovarian Insufficiency; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Vagina | 2019 |
AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1α/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Pro- and Anti-Inflammatory Cytokine Expression Levels in Macrophages; An Approach to Develop Indazolpyridin-Methanones as a Novel Inflammation Medication.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Benzylidene Compounds; Breast Neoplasms; Cell Line; Cell Survival; Cyclooxygenase 2; Cytokines; Humans; Indazoles; Macrophages; Mice; Molecular Docking Simulation; Pyridines | 2020 |
Targeting Discoidin Domain Receptor 1 (DDR1) Signaling and Its Crosstalk with β
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Collagen Type I; Discoidin Domain Receptor 1; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Kinase 1; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Indazoles; Integrin beta1; Integrin beta4; MAP Kinase Signaling System; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitoxantrone; Neoplasm Proteins; Piperazines; Tumor Microenvironment | 2020 |
Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series.
Topics: Adenosine Diphosphate Ribose; Breast Neoplasms; Female; Humans; Indazoles; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Thiazoles; Thiophenes; Thrombocytopenia | 2020 |
Potentiation of the Effect of Lonidamine by Quercetin in MCF-7 human breast cancer cells through downregulation of MMP-2/9 mRNA Expression.
Topics: Apoptosis; Breast Neoplasms; Down-Regulation; Humans; Indazoles; Matrix Metalloproteinase 2; MCF-7 Cells; Quercetin; RNA, Messenger | 2020 |
Evaluation of the antiproliferative effects of the HASPIN inhibitor CHR-6494 in breast cancer cell lines.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indazoles; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Protein Serine-Threonine Kinases; Pyridazines; RNA, Messenger; Transplantation, Heterologous | 2021 |
High MMP-11 expression associated with low CD8+ T cells decreases the survival rate in patients with breast cancer.
Topics: Aminopyridines; Breast Neoplasms; CD8-Positive T-Lymphocytes; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Lymphocytes, Tumor-Infiltrating; Matrix Metalloproteinase 11; MCF-7 Cells; Middle Aged; Pyrazoles; Receptor, ErbB-2; Sulfonamides; Survival Analysis; Survival Rate; Tumor Microenvironment | 2021 |
Niraparib for Advanced Breast Cancer with Germline
Topics: BCG Vaccine; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Germ Cells; Germ-Line Mutation; Humans; Indazoles; Nitriles; Piperidines | 2021 |
Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
Topics: Animals; Antineoplastic Agents, Immunological; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Epithelium; ErbB Receptors; Female; Humans; Indazoles; Lapatinib; Mammary Glands, Animal; Mice, Transgenic; Neoplasm Metastasis; Pertussis Toxin; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, G-Protein-Coupled; Signal Transduction; Sulfonamides; Trastuzumab; Up-Regulation | 2021 |
Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2017 |
Insulin-like growth factor-1 signaling is responsible for cathepsin G-induced aggregation of breast cancer MCF-7 cells.
Topics: Autocrine Communication; Axitinib; Breast Neoplasms; Cathepsin G; Cell Aggregation; Female; Humans; Imidazoles; Indazoles; Indoles; Insulin-Like Growth Factor I; MCF-7 Cells; Phosphorylation; Pyrazines; Pyrroles; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Small Molecule Libraries; Sunitinib | 2017 |
Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Down-Regulation; Female; Heterografts; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mutation; Neoplasm Metastasis; Transfection; Ubiquitin-Protein Ligases; Ubiquitination | 2017 |
Pazopanib Sensitivity in a Patient With Breast Cancer and
Topics: Breast Neoplasms; Female; Gene Amplification; Humans; Indazoles; Middle Aged; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Sulfonamides | 2017 |
Effect of Microenvironmental pH Modulation on the Dissolution Rate and Oral Absorption of the Salt of a Weak Acid - Case Study of GDC-0810.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Biological Availability; Breast Neoplasms; Cinnamates; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Excipients; Fasting; Female; Gastrointestinal Absorption; Healthy Volunteers; Humans; Hydrogen-Ion Concentration; Indazoles; Meglumine; Receptors, Estrogen; Sodium Bicarbonate; Solubility; Tablets | 2018 |
Micelle System Based on Molecular Economy Principle for Overcoming Multidrug Resistance and Inhibiting Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Delayed-Action Preparations; Doxorubicin; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Hydrazines; Indazoles; Lung; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Inbred BALB C; Micelles; Nanomedicine; Nitric Oxide; Rats; Rats, Sprague-Dawley; Tissue Distribution; Treatment Outcome; Vitamin E; Xenograft Model Antitumor Assays | 2018 |
PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Humans; Indazoles; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Ribonucleotides; Sulfonamides | 2018 |
Inhibiting pulmonary metastasis of breast cancer based on dual-targeting graphene oxide with high stability and drug loading capacity.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Doxorubicin; Female; Graphite; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Sulfonamides | 2018 |
Distinct apoptotic blocks mediate resistance to panHER inhibitors in HER2+ breast cancer cells.
Topics: bcl-X Protein; Benzothiazoles; Biphenyl Compounds; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Isoquinolines; Nitrophenols; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolinones; Quinolines; Receptor, ErbB-2; Sulfonamides | 2018 |
The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Female; Furans; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Ketones; Mutation; Phthalazines; Piperazines; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Vinblastine; Vinorelbine | 2018 |
Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling.
Topics: Animals; Aspirin; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Disease Models, Animal; Female; Indazoles; Lung Neoplasms; Macrophages; Mice; Mice, Inbred BALB C; NF-kappa B; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; RAW 264.7 Cells; Signal Transduction; Sulfonamides | 2018 |
OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers.
Topics: Breast Neoplasms; Drug Resistance, Neoplasm; Female; Hep G2 Cells; Humans; Indazoles; Liver Neoplasms; Male; MCF-7 Cells; MicroRNAs; Neoplasm Metastasis; Phenylurea Compounds; RNA, Neoplasm | 2018 |
Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma
Topics: Apoptosis; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Cell Cycle; Cell Line, Tumor; Chemoprevention; CRISPR-Cas Systems; DNA Breaks, Double-Stranded; DNA Repair; Female; Germ-Line Mutation; HeLa Cells; Humans; Indazoles; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Phthalazines; Piperazines; Piperidines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Spheroids, Cellular; Synthetic Lethal Mutations; X-ray Repair Cross Complementing Protein 1 | 2018 |
YLT-11, a novel PLK4 inhibitor, inhibits human breast cancer growth via inducing maladjusted centriole duplication and mitotic defect.
Topics: Acetamides; Antineoplastic Agents; Breast Neoplasms; CDC2 Protein Kinase; cdc25 Phosphatases; Cell Line, Tumor; Cell Proliferation; Centrioles; Cyclin-Dependent Kinase Inhibitor p21; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; MCF-7 Cells; Mitosis; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrimidines; RNA, Small Interfering; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Tricyclic Indazoles-A Novel Class of Selective Estrogen Receptor Degrader Antagonists.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dogs; Drug Screening Assays, Antitumor; Estrogen Receptor alpha; Estrogen Receptor Antagonists; Heterocyclic Compounds, 3-Ring; Humans; Indazoles; Male; MCF-7 Cells; Mice, SCID; Microsomes, Liver; Molecular Structure; Rats; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2019 |
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Topics: Animals; Antibodies; Base Sequence; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Female; Gene Expression Profiling; Humans; Immunotherapy; Indazoles; Interferons; Mice; Mice, Inbred C57BL; Mutation; Neoplasm Transplantation; Ovarian Neoplasms; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Programmed Cell Death 1 Receptor | 2019 |
The LXR-623-induced long non-coding RNA LINC01125 suppresses the proliferation of breast cancer cells via PTEN/AKT/p53 signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; PTEN Phosphohydrolase; RNA, Long Noncoding; Signal Transduction; Transplantation, Heterologous; Tumor Suppressor Protein p53; Up-Regulation | 2019 |
Therapeutic strategies to induce ERα in luminal breast cancer to enhance tamoxifen efficacy.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Everolimus; Female; Humans; Hydroxamic Acids; Indazoles; MCF-7 Cells; Paclitaxel; Sulfonamides; Tamoxifen; Tumor Cells, Cultured | 2019 |
Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility.
Topics: Animals; Breast Neoplasms; Cell Proliferation; Cinnamates; Drug Resistance, Neoplasm; Estrogen Receptor Antagonists; Female; Fulvestrant; HEK293 Cells; Heterografts; Humans; Indazoles; Ligands; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Polymorphism, Single Nucleotide; Proteolysis; Receptors, Estrogen; Signal Transduction; Transcription, Genetic | 2019 |
Pazopanib inhibits the activation of PDGFRβ-expressing astrocytes in the brain metastatic microenvironment of breast cancer cells.
Topics: Animals; Antineoplastic Agents; Astrocytes; Brain Neoplasms; Breast Neoplasms; Drug Evaluation, Preclinical; Female; Humans; Indazoles; Mice; Neoplasm Micrometastasis; Neoplasm Proteins; Neoplasm Transplantation; Neuroglia; Phosphorylation; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Sulfonamides; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal, Humanized; Blotting, Western; Breast Neoplasms; Cell Culture Techniques; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Indazoles; MCF-7 Cells; Neuregulin-1; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sulfonamides; Trastuzumab | 2013 |
CLC604 preferentially inhibits the growth of HER2-overexpressing cancer cells and sensitizes these cells to the inhibitory effect of Taxol in vitro and in vivo.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Etoposide; Female; Furans; HSP90 Heat-Shock Proteins; Humans; Indazoles; Mice; Mice, SCID; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Pyrazoles; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2013 |
The 18-kDa translocator protein (TSPO) disrupts mammary epithelial morphogenesis and promotes breast cancer cell migration.
Topics: Acinar Cells; Apoptosis; Benzodiazepinones; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Size; Disease Progression; Humans; Indazoles; Isoquinolines; Ligands; Mammary Glands, Human; Neoplasm Invasiveness; Receptors, GABA | 2013 |
Differential sensitivities to lactate transport inhibitors of breast cancer cell lines.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Coumaric Acids; Female; Humans; Immunohistochemistry; Indazoles; Inhibitory Concentration 50; Monocarboxylic Acid Transporters; Quercetin; RNA, Small Interfering; Transfection | 2014 |
Integrin α(v)β₃-targeted radiotracer (99m)Tc-3P-RGD₂ useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α(v)β₃ RGD₂ therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Disease Models, Animal; Drug Monitoring; Indazoles; Integrin alphaVbeta3; Mice; Phenylurea Compounds; Radioactive Tracers; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2013 |
More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Indazoles; Indicators and Reagents; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2; Signal Transduction; Sulfonamides; Wound Healing | 2014 |
YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Enhancer of Zeste Homolog 2 Protein; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mammary Neoplasms, Experimental; Mice; Polycomb Repressive Complex 2; Proto-Oncogene Proteins c-cbl; Structure-Activity Relationship | 2014 |
VAV3 mediates resistance to breast cancer endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles | 2014 |
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; Female; Histones; Humans; Hydrogen Peroxide; Indazoles; Lung Neoplasms; Male; Microscopy, Fluorescence; Oxidants; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Rad51 Recombinase; Radiation-Sensitizing Agents; Tumor Stem Cell Assay; Tumor Suppressor Protein p53 | 2014 |
Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Centrioles; Female; Gene Expression; Gene Knockdown Techniques; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Protein Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Polo-like kinase 4 inhibition: a strategy for cancer therapy?
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Indazoles; Indoles; Protein Serine-Threonine Kinases | 2014 |
A PLK4 inhibitor has single-agent activity in preclinical tumor models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Indazoles; Indoles; Protein Serine-Threonine Kinases | 2014 |
Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.
Topics: Acids; Adenosine Triphosphate; Animals; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; Drug Synergism; Energy Metabolism; Female; Humans; Hydrogen-Ion Concentration; Indazoles; Intracellular Space; Magnetic Resonance Spectroscopy; Male; Mice, Nude; Monocarboxylic Acid Transporters; Ovarian Neoplasms; Prostatic Neoplasms; Symporters; Xenograft Model Antitumor Assays | 2015 |
Multiclass comparative virtual screening to identify novel Hsp90 inhibitors: a therapeutic breast cancer drug target.
Topics: Adenine; Anisoles; Antineoplastic Agents; Benzamides; Binding Sites; Breast Neoplasms; Catechin; Databases, Chemical; Drug Discovery; Female; Gene Expression; Glycine; Heterocyclic Compounds, 2-Ring; High-Throughput Screening Assays; HSP90 Heat-Shock Proteins; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Indazoles; Ligands; Molecular Docking Simulation; Protein Binding; Pyrazoles; Pyridines; Static Electricity; Structure-Activity Relationship; User-Computer Interface | 2015 |
Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Synergism; Ellagic Acid; Enzyme Inhibitors; Female; Humans; Indazoles; Mice; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Evaluating an ER Degrader for Breast Cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cinnamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Mutation; Receptors, Estrogen; Treatment Outcome | 2015 |
[Lonidamine induces apoptosis via endoplasmic reticulum stress response and down-regulating cIAP expression in human breast carcinoma MCF-7 cells].
Topics: Apoptosis; Breast Neoplasms; Caspase 8; Cell Proliferation; Down-Regulation; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Humans; Indazoles; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Ubiquitin-Protein Ligases; Up-Regulation | 2015 |
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cinnamates; Drug Resistance, Neoplasm; Estrogen Receptor Antagonists; Female; Indazoles; Rats; Structure-Activity Relationship; Tamoxifen; Xenograft Model Antitumor Assays | 2015 |
New 1H-Benzo[f]indazole-4,9-diones Conjugated with C-Protected Amino Acids and Other Derivatives: Synthesis and in Vitro Antiproliferative Evaluation.
Topics: Amino Acids; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; In Vitro Techniques; Indazoles; Molecular Structure; Stomach Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2015 |
Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Indazoles; MCF-7 Cells; Mice; Mice, Inbred NOD; Mutation; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Therapeutic Index | 2016 |
Positive response of a primary leiomyosarcoma of the breast following salvage hyperthermia and pazopanib.
Topics: Breast Neoplasms; Female; Humans; Hyperthermia, Induced; Indazoles; Leiomyosarcoma; Middle Aged; Pyrimidines; Sulfonamides | 2018 |
The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cinnamates; Disease Models, Animal; Heterografts; Humans; Indazoles; Mice; Prospective Studies; Rats; Receptors, Estrogen; Treatment Outcome | 2016 |
Obviating the Need for Serial Biopsies Through Random Assignment.
Topics: Anastrozole; Biopsy; Breast Neoplasms; Humans; Indazoles; Phosphatidylinositol 3-Kinases; Receptors, Estrogen; Sulfonamides | 2017 |
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.
Topics: Aminopyridines; Animals; Apoptosis; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Indazoles; MCF-7 Cells; Mice; Phosphatidylinositol 3-Kinases; Piperazines; Protein Serine-Threonine Kinases; Purines; Pyridines; Pyrimidines; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2017 |
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Ligands; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sulfonamides; Trastuzumab | 2009 |
Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Enzyme Inhibitors; Humans; Indazoles; Lapatinib; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sulfonamides; Taxoids; Trastuzumab; Xenograft Model Antitumor Assays | 2009 |
Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Division; Cell Line, Tumor; Enzyme Activation; Epithelial Cells; Female; Fibrocystic Breast Disease; Flow Cytometry; Humans; Immunoblotting; Indazoles; Indoles; Neoplasm Metastasis; Proto-Oncogene Proteins c-akt; Sirolimus; Survivors | 2010 |
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Female; Gene Expression Profiling; Humans; Indazoles; Mammary Neoplasms, Experimental; Mice; Mutation; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Predictive Value of Tests; Receptor, ErbB-2; Sensitivity and Specificity; Sulfonamides; Xenograft Model Antitumor Assays | 2010 |
Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Topics: Animals; Biomarkers; Breast Neoplasms; Cell Division; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Sulfonamides | 2010 |
PIKing the right patient.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Disease Models, Animal; Female; Gene Expression Profiling; Humans; Indazoles; Mice; Mitogen-Activated Protein Kinases; Mutation; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2; Sulfonamides; Transcription Factors | 2010 |
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Synergism; Female; Humans; Indazoles; Mice; Mutation; Neoplasm Transplantation; Ovarian Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sulfonamides | 2010 |
Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Carriers; Drug Resistance, Multiple; ErbB Receptors; Female; Humans; Indazoles; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Polymers | 2011 |
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Pyrimidines; Receptor, ErbB-2; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Female; Indazoles; Mice; Mice, Nude; Nanoparticles; Nanotechnology; Paclitaxel | 2011 |
Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Axitinib; Biological Transport; Blood-Brain Barrier; Brain; Breast Neoplasms; Cell Line; Dogs; Female; Humans; Imidazoles; Indazoles; Male; Mice; Mice, Knockout; Protein Kinase Inhibitors | 2011 |
Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners?
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Guidelines as Topic; Humans; Imidazoles; Indazoles; Multicenter Studies as Topic; Neoplasm Proteins; Precision Medicine; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Research Design; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Breast Neoplasms; Caspases; Cell Line, Tumor; Drug Synergism; Female; Humans; Indazoles; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Nitrophenols; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Proto-Oncogene Proteins c-bcl-2; Sulfonamides | 2011 |
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Topics: Animals; Benzimidazoles; Blotting, Western; BRCA1 Protein; Breast Neoplasms; Carrier Proteins; CDC2 Protein Kinase; Cell Death; Cell Line, Tumor; DNA Damage; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Indoles; Male; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Nuclear Proteins; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; RNA-Binding Proteins | 2011 |
The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indazoles; MAP Kinase Signaling System; Melanoma; Mice; Neovascularization, Pathologic; Proto-Oncogene Proteins B-raf; Pyrimidines; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Chemoradiotherapy; Female; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Nude; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CCL2; Female; Humans; Indazoles; Macrophages; Male; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Transplantation; NF-kappa B; Propionates; Prostatic Neoplasms; Signal Transduction | 2012 |
YC-1 exerts inhibitory effects on MDA-MB-468 breast cancer cells by targeting EGFR in vitro and in vivo under normoxic condition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; G1 Phase; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Oxygen; RNA, Messenger; STAT3 Transcription Factor; Tumor Burden | 2012 |
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Survival; Docetaxel; Drug Synergism; Female; Humans; Indazoles; Mice; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Sulfonamides; Taxoids | 2012 |
Novel pyrazole and indazole derivatives: synthesis and evaluation of their anti-proliferative and anti-angiogenic activities.
Topics: Acetophenones; Angiogenesis Inhibitors; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Female; HeLa Cells; Humans; Indazoles; Inhibitory Concentration 50; Mice; Pyrazoles; Tetralones | 2012 |
The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Down-Regulation; Female; Humans; Indazoles; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases | 2012 |
Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status.
Topics: Animals; Blotting, Western; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Estrogen Antagonists; Estrogen Receptor alpha; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Nude; Neoplastic Stem Cells; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tamoxifen; Transplantation, Heterologous | 2013 |
Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI.
Topics: Animals; Axitinib; Breast Neoplasms; Female; Humans; Image Enhancement; Imidazoles; Indazoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous | 2005 |
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Axitinib; Breast Neoplasms; Capillary Permeability; Cell Proliferation; Contrast Media; Female; Imidazoles; Indazoles; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; src-Family Kinases; Treatment Outcome | 2007 |
Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Mice; Mice, Inbred C3H; Mice, Nude; Recombinant Fusion Proteins; Transfection | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors.
Topics: Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Checkpoint Kinase 1; Crystallography, X-Ray; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Indazoles; Male; Models, Molecular; Molecular Structure; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Structure-Activity Relationship | 2007 |
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dogs; Epidermal Growth Factor; ErbB Receptors; Ether-A-Go-Go Potassium Channels; Female; Hepatocytes; Humans; Indazoles; Keratinocytes; Lapatinib; Male; Metabolic Clearance Rate; Mice; Mice, Nude; Mice, SCID; Microsomes; Molecular Structure; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; Receptor, ErbB-2; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
Intracellular localization of the antitumour drug adriamycin in living cultured cells: a confocal microscopy study.
Topics: Breast Neoplasms; Cell Nucleus; Cytoplasm; Doxorubicin; Drug Resistance, Multiple; Fluorescence; Humans; Indazoles; Melanoma; Microscopy, Confocal; Tumor Cells, Cultured; Verapamil | 1994 |
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.
Topics: Adenocarcinoma; Alkylating Agents; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Drug Synergism; Female; Fibrosarcoma; Humans; Indazoles; Male; Mice; Mice, Inbred C3H; Novobiocin; Topotecan; Tumor Cells, Cultured | 1993 |
Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carmustine; Cell Line; Doxorubicin; Drug Resistance; Female; Glioblastoma; Humans; Indazoles; Treatment Failure; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1996 |
Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells.
Topics: Adenine Nucleotides; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Glucose; Hexokinase; Humans; Indazoles; Mitochondria; Tumor Cells, Cultured | 1996 |
Comparison of action of the anti-neoplastic drug lonidamine on drug-sensitive and drug-resistant human breast cancer cells: 31P and 13C nuclear magnetic resonance studies.
Topics: Antineoplastic Agents; Breast Neoplasms; Carbon Isotopes; Deoxyglucose; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Magnetic Resonance Spectroscopy; Phosphorus Isotopes; Tumor Cells, Cultured | 1997 |
Saporin 6 and lonidamine in primary cell cultures from human breast carcinomas: a synergistic effect.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Cycle; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Immunotoxins; Indazoles; Middle Aged; N-Glycosyl Hydrolases; Phenotype; Plant Proteins; Receptors, Estrogen; Receptors, Progesterone; Ribosome Inactivating Proteins, Type 1; Saporins; Tumor Cells, Cultured | 1997 |
Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Division; Cisplatin; Drug Administration Schedule; Drug Synergism; Epirubicin; Humans; Indazoles; Tumor Cells, Cultured | 1997 |
Noninvasive real-time monitoring of intracellular cancer cell metabolism and response to lonidamine treatment using diffusion weighted proton magnetic resonance spectroscopy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Diffusion; Dose-Response Relationship, Drug; Humans; Indazoles; Ischemia; Magnetic Resonance Spectroscopy; Melanoma, Experimental; Mice; Monitoring, Physiologic; Protons; Signal Processing, Computer-Assisted; Tumor Cells, Cultured | 2000 |
In vitro potentiation by lonidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Indazoles; Lethal Dose 50; Male; Receptors, Estrogen; Receptors, Progesterone; Tumor Cells, Cultured | 1992 |
Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line.
Topics: Antineoplastic Agents; Biological Transport; Breast Neoplasms; Cell Line; Cell Survival; Doxorubicin; Drug Resistance; Drug Synergism; Female; Humans; Indazoles; Kinetics | 1991 |
A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Humans; Indazoles; Magnetic Resonance Spectroscopy; Menopause; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen | 1991 |
Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carboplatin; Carmustine; Drug Resistance; Drug Screening Assays, Antitumor; Drug Synergism; Fibrosarcoma; Humans; Indazoles; Mammary Neoplasms, Animal; Mice; Organoplatinum Compounds; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1991 |
The pharmacokinetics of oral lonidamine in breast and lung cancer patients.
Topics: Absorption; Administration, Oral; Aged; Antineoplastic Agents; Breast Neoplasms; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Tolerance; Female; Fluorescence; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Tablets; Time Factors | 1991 |
Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Topics: Alkylating Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cell Line; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Indazoles; Pyrazoles; Time Factors; Tumor Cells, Cultured | 1989 |
Phase II study of lonidamine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Pyrazoles | 1989 |
Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Canada; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Indazoles; Middle Aged; Neoplasm Metastasis; Pyrazoles; Receptors, Estrogen | 1986 |